A Canadian pharmaceutical company announced Monday its intention to pursue a major public stock offering that could breathe new life into Toronto’s struggling initial public offering landscape.
Apotex Health revealed plans to sell between 41.7 million and 50 million shares priced between C$20 and C$24 each, targeting gross proceeds of C$1 billion as part of its Toronto Stock Exchange debut.
The health company plans to generate approximately C$850 million through new share issuance, while current stakeholders will divest roughly C$150 million worth of existing stock during the offering process.
This represents among the most significant TSX listings attempted this year, following several years of minimal public offering activity as corporations steered clear of lackluster market conditions when seeking new funding.
Nevertheless, growing economic optimism combined with an improving TSX performance has sparked renewed enthusiasm, prompting companies across technology, natural resources and additional sectors to reconsider their public offering strategies.
Earlier this year, Toronto-based quantum computing company Xanadu Quantum Technologies completed its public debut through a special purpose acquisition company merger, securing dual listings on both Nasdaq and TSX while raising approximately $300 million.
The pharmaceutical firm, which serves customers across roughly 70 nations throughout North and South America, reported revenue increases of approximately 8% during the past four fiscal years, driven primarily by its generic drug operations through emphasis on first-to-market products and expansion into higher-value segments including specialty generics, branded medications, and biosimilars.
The offering’s underwriting team features RBC Capital Markets, TD Securities, and Scotiabank, while BMO Capital Markets and Jefferies serve as joint bookrunners, according to the company’s press release.
